Dani Bancroft, Author at Labiotech.eu - Page 7 of 23

About

Former Editor, now flitting back and forth as a freelancer. Originally from London and studied Zoology at the University of Reading, UK. Previous work includes having written for The Spark University Newspaper and the Wellcome Trust.

Articles by Dani Bancroft

apogenix glioblastoma cancermark german apg101

News and Trends 17 Feb 2016

Brain Cancer Biomarker is a Magnet for Public Money in Germany

Apogenix (Germany) has been granted €3M for a personalized medicine to treat glioblastoma. It will also use this funding to develop a companion diagnostic test using a specific cancer biomarker, which other German biotechs are also attempting to do… This Heidelberg based-biotech (which we visited on our Labiotech tour of South Germany) is focused on the development of protein Immuno-Oncology therapeutics to treat […]

February 17, 2016 - 3 minutesmins - By Dani Bancroft

clinical depression glasgow ets6103 e therapeutics

News and Trends 16 Feb 2016

Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic

I mean, Clinical depression is a tough indication for Biotech to tackle – particularly when facing off a ’55-year old’ generic (amitriptyline). But e-Therapeutics in Oxford (UK) has more to offer in its pipeline, despite this phase IIb failure in Glasgow. The trial’s aims were to determine whether ETS6103 was an antidepressant capable of treating the patients for […]

February 16, 2016 - 3 minutesmins - By Dani Bancroft

albert folch lab microfluidics millifluidic seventure

News and Trends 15 Feb 2016

‘Every Droplet Counts’ with €1M Investment into French Microfluidic Start-Up

MilliDrop (France) designs and develops cell culture machines based on millifluidic technology for bacterial research and diagnostics, and has now secured a €1M fund-raising from Seventure. Millidrop will use the fund to start producing trial runs of its first machine, the MilliDrop Analyzer. This machine uses millifluidics technology to culture and analyse micro-organisms. The company is also under the Pierre-Gilles […]

February 15, 2016 - 3 minutesmins - By Dani Bancroft

genomics england illumina 100 project partner uk

News and Trends 12 Feb 2016

World’s Largest Genome Sequencing Project partners with Global Leader in NGS

Genomics England (UK) today announce a partnership with the Next-Generation Sequencing Giant, Illumina (US), to develop a platform that can be used to improve and automate genome interpretation as part of the 100,000 Genome Project. The tools will operate within the Genomics England secure database to enable researchers and clinicians to access information and reports more readily. […]

February 12, 2016 - 2 minutesmins - By Dani Bancroft

sanofi genzyme biotech finance 4bn

News and Trends 11 Feb 2016

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […]

February 11, 2016 - 3 minutesmins - By Dani Bancroft

deinove carotenoids synbio greentech deinochem

News and Trends 9 Feb 2016

Synthetic Biology Breakthrough in Production of Natural Carotenoids

The SynBio Biotech, Deinove (France), is hoping to break into the Carotenoid market for food, cosmetics and animal feed. Now, with their Deinococcus platform they have made several major advancements in their endeavours. Deinove also partnered with the Canadian company POS Bio-Sciences last year to try and kickstart the long-term project. Carotenoids are part of the isoprenoid family, which is the main area of […]

February 9, 2016 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT

carat car t cell eu commission fund

News and Trends 8 Feb 2016

The European Union Finances the Future of CAR-T Manufacturing

CAR-T is the way forward in Cancer therapeutics, which is one of the leading causes of Mortality in the Western world. Now this European consortium has amassed €6M for a more unified approach to CAR-T under a European Union Commission program. In response to this major health issue Miltenyi Biotec (Germany) coordinates the new EU-funded project […]

February 8, 2016 - 3 minutesmins - By Dani Bancroft

tedopi nsclc lung cancer ose pharma atlante

News and Trends 8 Feb 2016

French Biotech Launches Phase III Global Trial for Lung Cancer Drug

OSE Pharma (France) has initiated the US phase III trial, Atalante 1. This global, pivotal trial will evaluate Tedopi, the company’s lead product, for advanced non-small cell lung cancer (NSCLC). The phase III study was initiated in Europe in early 2016, so the screening of eligible patients diagnosed with non-small cell lung cancer is now actively ongoing in […]

February 8, 2016 - 2 minutesmins - By Dani Bancroft

forbes under 30 biotech eu innovators

News and Trends 8 Feb 2016

Here are 8 of Forbes’ Under 30 Year Olds Transforming European Biotech

Here are 8 of the top European innovators under 30 which are part of the Biotech Ecosystem… After reading Forbes ’30 Under 30′ ranking in the Science and Healthcare field in Europe, we decided to list a few of these impressive individuals – one as young as 18 years old! The panel of judges was made up […]

February 8, 2016 - 4 minutesmins - By Dani Bancroft

riboxx life sciences rna cancer tollys biotech

News and Trends 5 Feb 2016

German RNA Specialist Could Break French Biotech into the Cancer Ecosystem

Riboxx Life Sciences (Germany) has licensed out its drug development platform APOXXIM to a small biotech, Tollys SAS in Lyon (France) to investigate a specific type of cancer therapy. Riboxx develops customized and tailor-made molecular tools for gene silencing in vitro and in vivo through RNA interference via small interfering RNA (siRNA) and microRNA (miRNA). The company has two […]

February 5, 2016 - 2 minutesmins - By Dani Bancroft

3d bioprinting brain neurology harvard inserm cnrs finland

News and Trends 4 Feb 2016

Finland, France and Harvard Bioprint Brains to Understand the 3D Structure

Researchers at Harvard University in collaboration with French and Finnish academic institutions have managed to 3D-bioprint a brain with the distinctive folds; An essential adaptation for our cognitive development. Harvard University worked with the CNRS at Aix Marseille Université (France), Institut Mines-Telecom INSERM (France) and the University of Jyväskylä (Finland). The team then published in Nature Physics what they discovered […]

February 4, 2016 - 3 minutesmins - By Dani Bancroft

llama leo pharma argen x skin milestone inflammatory

News and Trends 3 Feb 2016

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody pipeline which Leo Pharma (Denmark), is developing to treat inflammatory skin conditions. These llama mAb platforms allow arGEN-X to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. This is a similar approach to which Ablynx […]

February 3, 2016 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT